https://www.selleckchem.com/pr....oducts/pf-04957325.h
.gov/ct2/show/NCT00301561 . ClinicalTrials.gov NCT00301561. Registered on March 13, 2006, url https//clinicaltrials.gov/ct2/show/NCT00301561 .Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an established standard of care for patients with advanced hormone receptor-positive breast cancer. The canonical mechanism underlying CDK4/6 inhibitor activity is the suppression of phosphorylation of the retinoblastoma tumor suppressor protein, which serves to prevent cancer cell proliferation. Recent data sugges
Curtir
Comentario
Compartilhar
